> l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1Courier New1Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)**_($* #,##0_);_($* (#,##0);_($* ""_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* ""_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* ""??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* ""??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)60%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0) + ) , * Ј ~~ ؈ ~~#؈ ~~"؈ ~~ ؈ ~~8#܈ ~~3#܈ ~~9"܈ ~~4#܈ ~~7#܈ ~~9#܈ ~~"؈ ~~83ffff̙̙3f3fff3f3f33333f33NO TITLENO TITLE (1)&NO TITLE (2)"FGel Electrophoresis Systems&VThe divestiture of the remainindSusan LuscinskitSusan Luscinski (1)Income StatementSusan Luscinski (2)& The following section of this A&Overview of Cash Flows for the %
Overview of Cash Flows for (1)#!Impact of Foreign CurrenciesX.Summary Compensation8Beneficial Ownership#@DImpact of Foreign Curren (1)&XI NDEX TO CONSOLIDATED FINANCIAgh
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows&EConsolidated Statements of Stoc&WConsolidated Statements of (1)&[dConsolidated Statements of (2)&+sConsolidated Statements of (3) Panlab sl
#Anthos
Anthos (1)ϼ
Anthos (2)`
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)&
Anthos (8)=6
Anthos (9)jMAnthos (10),hAnthos (11)zwAnthos (12)Anthos (13)Anthos (14) Anthos (15)KAnthos (16)Anthos (17)&KDistribution and Dilutive Effec&#Distribution and Dilutive E (1)&Distribution and Dilutive E (2)&d)Distribution and Dilutive E (3)&/CDistribution and Dilutive E (4)&)SDistribution and Dilutive E (5)&[mDistribution and Dilutive E (6)&{Distribution and Dilutive E (7)&Distribution and Dilutive E (8)&nDistribution and Dilutive E (9)&4Distribution and Dilutive (10)&Distribution and Dilutive (11)&@Distribution and Dilutive (12)&MDistribution and Dilutive (13)Income Statement (2)1Income Statement (3)&sDistribution and Dilutive (14)&׆Distribution and Dilutive (15)&Distribution and Dilutive (16)
l j
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>NO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }%}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008NO TITLE Delaware
043306140'
(State or other jurisdiction of
(I.R.S. Employer&Incorporation or organization)Identification No.)
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@tPrfZ2=PF0*8X>
@
l e&
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }%}$ }1
HARVARD BIOSCIENCE INC10K
03/11/2008NO TITLE Title of each class 1 )Name of each exchange on which registered%
Common Stock, $0.01 par value
#
The NASDAQ Stock Market LLC'Preferred Stock Purchase Rights
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@tPQE9=PF0*8X>
@
l 6;sE
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }y
}$ }}$ }:}$ }
6
HARVARD BIOSCIENCE INC10K
03/11/2008NO TITLE Item
PART I
~
Business~
1ARisk Factors~
.
1B
!
Unresolved Staff Comments
~
V~
Properties~
V~
Legal Proceedings~
V~
3+Submission of Matters to a Vote of Security~
VHolders
4A,$Executive Officers of the Registrant~
ZPART II~
.&Market for Registrant?s Common Equity,~
^.&Related Stockholder Matters and Issuer&Purchases of Equity Securities~
Selected Financial Data~
f~
,$Management?s Discussion and Analysis~
n80of Financial Condition and Results of Operations
7A0(Quantitative and Qualitative Disclosures~
About Market Risk~
".&Financial Statements and Supplementary~
Data~
&5Changes in and Disagreements with Accountants~
.&on Accounting and Financial DisclosureDlt n9n,S(@s !"#$%&'()*+,./012345
9A Controls and Procedures ~
!!
!9B!!Other Information!~
!"PART III""""""##~
#*#7#/Directors, Executive Officers of the Registrant#~
#$$$$ $and Corporate Governance%%~
%.%%Executive Compensation%~
%&&~
&2&0&(Security Ownership of Certain Beneficial&~
&''''5'Owners and Management and Related Stockholder(((((Matters))~
)6)7)/Certain Relationships and Related Transactions,)~
)****!*and Director Independence++~
+:+.+&Principal Accountant Fees and Services+~
+,PART IV,,,,,,~
>2*Exhibits and Financial Statement Schedules~
....2.*Index to Consolidated Financial Statements..F1/////
Signatures//00000
Exhibit Index0012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0 (EW{ A=PF0*8X>
@554433
l V
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }}$ }<}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008#Gel Electrophoresis Systems
Continuing Discontinued
Total
Operations
Operations
United States~
~
:~
FUnited Kingdom~
?~
Spain
~
?
~
Austria~
v ?~
vGermany~
:~
~
FCanada~
?~
France~
?~
Total~
:~
F~
~$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8yma
N"aO\=PF0*8X>
@
l ^d
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis SystemsSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008jbThe divestiture of the remaining portion of our Capital Equipment Business segment may disrupt our Name Age Position
Chane Graziano
~
,
$Chief Executive Officer and DirectorDavid Green~
President and Director
Bryce Chicoyne~
%Chief Financial Officer and TreasurerSusan Luscinski~
Chief Operating Officer$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0>2&#wkC=PF0*8X>
@
l s
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }I"}$
HARVARD BIOSCIENCE INC10K
03/11/2008Susan Luscinski$ Year Ended December 31, 2007 High Low
First Quarter
@
@Second QuarterQ@Q@
Third QuarterQ@zG@
Fourth Quarter
ffffff@
(\@$Year Ended December 31, 2006HighLow
First QuarterHzG@
ףp=
@Second QuarterQ@Q@
Third Quarter@q=
ףp@Fourth QuarterQ@@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6ymed@6sK=PF0*8X>
@
l 1
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiIncome StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$
HARVARD BIOSCIENCE INC10K
03/11/2008Susan Luscinski
12/02
12/03
12/04
12/05
12/06
12/07
Harvard Bioscience, Inc.
~
(\p@
Gza@
(\`@
qc@
p=
[a@Russell 2000~
hb@Hze@
(\f@
Gzj@Qj@NASDAQ Pharmaceutical~
Gzb@Qd@
d@
=
ףpmd@QNc@
NASDAQ Biotechnology
~
fffff^b@
d@
zG)g@
{Gf@
ףp=
Gg@$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hym3bzR=PF0*8X>
@
!
l FD
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Susan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }}$ }}
$ }}$ }}$ }}$
F
HARVARD BIOSCIENCE INC10K
03/11/2008Income Statement
( For The Years Ended December 31,
~
^
~
Z
~
V
~
R
~
N
%(in thousands, except per share data)%Statement of Operations Data:
Revenues
~
>
~
V
~
~
~
,
#Cost of product revenues(1)~
f~
:S
~
~
~
Gross profit~
t~
S
~
~
&~
JOperating expenses(1)~
~
V
~
~
&h~
6
Operating income~
~
ʇ
~
{
~
~
p#Other income (expense), net~
~
j
~
~
F~
2
0(Income from continuing operations before~
~
2
~
o
~
Fw~
F`income taxesIncome taxes~
~
~
~
0~
'
)!Income from continuing operations~
v~
vg
~
a
~
F~
8
%Discontinued operations(1)(2)
3+Income (loss) from discontinued operations,~
b~
s
~
j
~
~
net of tax7/Loss on disposition of discontinued operations,~
?
?
? ?Dlxlp VoWEI"&
!"#$%&'()*+,./0123456789:;<=>?
net of tax!!!!!!!!!! !
!!!
!!!!!!!"%Total income (loss) from discontinued""~
""t"""~
"s"" "
~
"j""
"~
""""~
"
"#operations, net of tax$$$$$$$$$$ $
$$$
$$$$$$$%Net income (loss)%%~
%%%%~
%n%% %
~
%
%%
%~
%f$%%%~
%B%&&&&&&&&&& &
&&&
&&&&&&& 'Income (loss) per share:''''''''' '
'''
'''''''7(/Basic earnings per common share from continuing((?((()\(?(( (
?((
(333333?(((Q?()
operations*Discontinued operations***(\ҿ****(\ҿ** *
***
**Q뱿****{Gz?*++++++++++ +
+++
+++++++.,&Basic earnings (loss) per common share,,{Gz,,,{Gz,, ,
,,
,{Gz?,,,Q?, 

..&Diluted earnings per common share from..Q?...zG?.. .
?..
.333333?...Q?./continuing operations0Discontinued operations000(\ҿ0000(\ҿ00 0
0ףp=
00
00{Gz0000{Gz?01111111111 1
111
111111102(Diluted earnings (loss) per common share22{Gz222{Gz22 2
p=
ף22
2Q?222Q?23333333333 3
333
3333333'4Weighted average common shares:444444444 4
444
4444444
5Basic55~
5555~
555 5
~
555
5~
5555~
556Diluted66~
6666~
666 6
~
666
6~
6666~
6677888As of December 31,899~
9^99~
9Z99 ~
9
V99
~
9R99~
9N9:::(in thousands):;Balance Sheet Data:;;;;;;;;; ;
;;;
;;;;;;;!<Cash and cash equivalents<~
<<<~
<6<< ~
<
Bw<<
~
<<<~
<~<=Working capital==~
=JQ===~
=&[== =
~
===
=~
====~
=s=>Total assets(3)>>~
>>>>~
>>> >
~
>>>
>~
>>>>~
>>.?&Longterm debt, net of current portion??~
?*W???~
?.?? ?
~
?҄??
?~
?"???~
??Dl~q[*.*.* ME6S>@ABCDE@Stockholders? equity(3)@@~
@f@@@~
@.c@@ @
~
@@@
@~
@^@@@~
@@AB$C____________________________1D)Created by Morningstar Document Research.0E(http://documentresearch.morningstar.com/>d=PF0*8X>
@z/EEDDCC<<<<<<
<<<<::999999
999988222222
2222......
....,,,,,,
,,,,((((((
((((
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income Statement!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0.}$ }}$ }U} $ }
HARVARD BIOSCIENCE INC10K
03/11/2008Susan Luscinski
Before Adjustments
After
Application of
Increase
Application ofSFAS No. 158
(Decrease) SFAS No. 158(in thousands)"
Deferred income tax assets
~
*
~
~
Total assets~
~
~
%Other liabilities?noncurrent~
~
# ~
>$Total liabilities~
)~
# ~
M.&Accumulated other comprehensive income~
ry~
~
z`"Total stockholders? equity~
&~
~
.c$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4ymsm;%~3wO=PF0*8X>
@
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }<(}$ }}$ }I }$}$ } }
$ }I }$}
$ }}$ }I }$
HARVARD BIOSCIENCE INC10K
03/11/2008jbThe following section of this Annual Report on Form 10K entitled #147;Management#146;s Discussion
~
^ % of ~
Z
% of
~
V % of
Revenue
Revenue
Revenue(in thousands)Total revenues~
>~
V
~
Cost of product revenues
~
f
I@
%
~
:S
~
%
~
YI@
%$Sales and marketing expenses~
¡(@ %~
n
)@ %
~
~~
2 %)!General & administrative expenses~
1@ %~
3@ %
~
N333332@ %&Research & development expense~
9@ %~
J1
ffffff@ %
~
.@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0c>2&6dw9eR;=PF0*8X>
@R
l ' S
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }:}$ }
}$ }U}
$ } }$
'
HARVARD BIOSCIENCE INC10K
03/11/2008?7Overview of Cash Flows for the years ended December 31,
~
^ ~
Z ~
V
(in thousands)
#Cash flows from operations:
Net loss~
~
n ~
)
!Changes in assets and liabilities
~
n
~
~
1)Other adjustments to operating cash flows~
~
~
F
1)Net cash provided by operating activities~
^~
~
.Q Investing activities:
%Acquisitions and divestitures~
~~
?"Other investing activities~
&~
f
~
2
%Net cash used in investing activities~
~
~
2 Financing activities:
*"Proceeds (repayments) of debt, net~
$~
~
"Other financing activities~
J~
~
0(Net cash provided by (used in) financing~
Z/~
j
~
>
activities/'Effect of exchange rate changes on cash~
~
~
j
Dli]QE+6"`X6
!
"
#
$
%
&
8 0Increase (decrease) in cash and cash equivalents ~
~
~
!!!!!!!!!! !
!!"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/xRv=PF0*8X>
@j
&&%%$$
l {
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }
}$ }
}$ } U}
$ }U}
$ }U}$ }U}$ }U
HARVARD BIOSCIENCE INC10K
03/11/2008?7Overview of Cash Flows for the years ended December 31,
Total ~
b ~
f
~
j
~
n ~
r 2013 and
Beyond(in thousands)
Notes payable~
y~
!~
U
~
$?
$?
$?
Operating leases
~
8
~
~
:
~
V
~
R
~
~
b
Total~
~
:~
a
~
~
R~
~
b
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0
i]QE=rp>oIAzrfZ2=PF0*8X>
@
l 
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Summary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }U5}$
HARVARD BIOSCIENCE INC10K
03/11/2008$Impact of Foreign Currencies4 ,If compared to the rate at December 31, 2007 Interest Expense
Increase(in thousands)'Interest rates increase by 1.0%~
'
Interest rates increase by 2.0%
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*=hxl`0r=PF0*8X>
@B
l 8
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }1}U
HARVARD BIOSCIENCE INC10K
03/11/2008Summary CompensationItem 11.Executive Compensation.
$____________________________1)Created by Morningstar Document Research.0
(http://documentresearch.morningstar.com/ th1%=PF0*8X>
@
l C
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }1}6
HARVARD BIOSCIENCE INC10K
03/11/2008Beneficial OwnershipItem 12.0(Security Ownership of Certain Beneficial 5 Owners and Management and Related Stockholder
Matters.$
____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$.,th {=PF0*8X>
@
l %jV;X
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial Ownership!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }$}$ }I;}$ }
%
HARVARD BIOSCIENCE INC10K
03/11/2008$Impact of Foreign Currencies~
. &Financial Statements. The consolidated
8
0financial statements of Harvard Bioscience, Inc.0(and its subsidiaries filed under Item 8:
Page2*Index to Consolidated Financial StatementsF1/'Report of Independent Registered PublicF2Accounting Firm6.Consolidated Balance Sheets as of December 31,F3
2007 and 2006%Consolidated Statements of OperationsF43+for the years ended December 31, 2007, 2006and 20050(Consolidated Statements of Stockholders?F5.&Equity and Comprehensive Income (Loss)3+for the years ended December 31, 2007, 2006and 2005%Consolidated Statements of Cash FlowsF63+for the years ended December 31, 2007, 2006and 20052*Notes to Consolidated Financial StatementsF7~
91Exhibits and Exhibit Index. See the Exhibit IndexDJ
lxl`$l SMi==^2 !"#$ 0 (included as the last part of this Annual!!,!$Report, which is incorporated herein$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/PlD=PF0*8X>
@$$##""
l g
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }7}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+I NDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page
/'Report of Independent Registered PublicF2Accounting Firm6
.Consolidated Balance Sheets as of December 31,
F3
2007 and 2006%Consolidated Statements of OperationsF43+for the years ended December 31, 2007, 2006and 20050(Consolidated Statements of Stockholders?F5.&Equity and Comprehensive Income (Loss)for the/'years ended December 31, 2007, 2006 and~
V%Consolidated Statements of Cash FlowsF63+for the years ended December 31, 2007, 2006and 20052*Notes to Consolidated Financial StatementsF7$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/Dglui]Q/0^'=PF0*8X>
@
l J}4=
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIAIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }}$ }} $
J
HARVARD BIOSCIENCE INC10K
03/11/2008
Balance Sheet December 31, December 31,
~
^
~
ZAssets Current assets:!
Cash and cash equivalents
~
~
6
%Accounts receivable, net of allowance~
~
./'for doubtful accounts of $378 and $364,respectivelyInventories~
~
ާ*"Deferred income tax assets?current ?~
V*"Other receivables and other assets~
%~
%.&Assets of discontinued operations?held~
B~
for saleTotal current assets~
P~
@*"Property, plant and equipment, net~
E~
H.&Deferred income tax assets?noncurrent~
j~
*"Amortizable intangible assets, net~
B~
f6.Goodwill and other indefinite lived intangible~
~
jvassetsOther assets~
~
nTotal assets~
~
Dm
l{oKRLcM7q_
!
"
#
$
%
&
'
(
)
*
+
,

.
/
0
1
2
3
4
5
6
7
8
9
:
;
<
=
>
?
,!$Liabilities and Stockholders? Equity!!!!!!!!"Current liabilities:""""""""#
Notes payable#~
#!##
#$?#$Accounts payable$$~
$W$$$~
$*F$%Deferred revenue%%~
%%%%~
%%$&Accrued income taxes payable&&~
&&&&~
&&'Accrued expenses''~
'@'''~
'RB'!(Other liabilities?current((~
((((~
((.)&Liabilities of discontinued operations))~
))))~
)*O)*********!+Total current liabilities++~
+V+++~
+r+1,)Longterm debt, less current installments,,~
,*W,,,~
,.,3+Deferred income tax liabilities?noncurrent~
b~
%.Other liabilities?noncurrent..~
.V...~
.>$./////////0Total liabilities00~
02000~
0M0111111111%2Commitments and contingencies222222223334Stockholders? equity:4444444435+Preferred stock, par value $0.01 per share,55 5?555 5?5#65,000,000 shares authorized07(Common stock, par value $0.01 per share,77~
7777~
7708(80,000,000 shares authorized; 35,512,68039+and 35,223,192 shares issued and 30,851,8967:/and 30,562,408 shares outstanding, respectively";Additional paidincapital;;~
;F
;;;~
;
;<Accumulated deficit<<~
<3<<<~
<I<.=&Accumulated other comprehensive income==~
=h===~
=z`=0>(Treasury stock, 4,660,784 common shares,>>~
>>>>~
>>?at costDlf>Q\8_+/@
A
B
C
D
E
F
G
H
I
@@@@@@@@@"ATotal stockholders? equityAA~
AfAAA~
A.cABBBBBBBBB2C*Total liabilities and stockholders? equityC~
CCC~
CCDDDDDDDDDEF$G____________________________1H)Created by Morningstar Document Research.0I(http://documentresearch.morningstar.com/
p=PF0*8X>
@zIIHHGGCCCC####
l Itd
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetShareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }}$ }}
$ }}$
I
HARVARD BIOSCIENCE INC10K
03/11/2008Income Statement
Years Ended December 31,
~
^
~
Z
~
V
Revenues~
>~
V ~
Cost of product revenues~
f~
:S
~
Gross profit~
t~
S
~
$Sales and marketing expenses~
¡~
n
~
~+#General and administrative expenses~
~
~
N)!Research and development expenses~
9~
J1
~
.)!Amortization of intangible assets~
~
~
Total operating expenses~
~
V
~
Operating income~
~
ʇ
~
{
Other income (expense):
Foreign exchange~
~
~
&Interest expense~
N~
N
~
Interest income~
~
b
~
Other, net~
~
:
~
J
#Other income (expense), net~
~
j
~
DFlxl
.P
GUT?
!
"
#
$
%
&
'
(
)
*
+
,

.
/
0
1
2
3
4
5
6
7
8
9
:
;
<
=
>
?
0!(Income from continuing operations before!!~
!!!!~
!2!! !
~
!o!"income taxes#Income taxes##~
####~
### #
~
##$$$$$$$$$$ $
$$)%!Income from continuing operations%%~
%v%%%~
%vg%% %
~
%a%&&&&&&&&&& &
&&'Discontinued operations''''''''' '
''.(&Loss from discontinued operations, net((~
(b(((~
(s(( (
~
(j()of tax7*/Loss on disposition of discontinued operations,**~
**** *?** *
*?*+
net of tax,,,,,,,,,, ,
,,0(Total loss from discontinued operations,~
"t~
s 
~
j.
net of tax////////// /
//0Net loss0~
000~
0n00 ~
0
01111111111 1
11 2Income (loss) per share:222222222 2
2273/Basic earnings per common share from continuing33?333)\(?33 3
?34
operations5Discontinued operations555(\ҿ5555(\ҿ55 5
556666666666 6
66#7Basic loss per common share77{Gz777{Gz77 7
78888888888 8
88.9&Diluted earnings per common share from99Q?999zG?99 9
?9:continuing operations;Discontinued operations;;;(\ҿ;;;;(\ҿ;; ;
;ףp=
;<<<<<<<<<< <
<<%=Diluted loss per common share=={Gz==={Gz== =
p=
ף=>>>>>>>>>> >
>>'?Weighted average common shares:????????? ?
??Dld8u&^L}gOyIX7r/@
A
B
C
D
E
F
G
H
@Basic@@~
@@@@~
@@@ @
~
@@AAAAAAAAAA A
AABDilutedBB~
BBBB~
BBB B
~
BBCCCCCCCCCC C
CCDE$F____________________________1G)Created by Morningstar Document Research.0H(http://documentresearch.morningstar.com/Yxl`8=PF0*8X>
@HHGGFF======
999999
777777
333333
000000
l 9>
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }$4}$ }}$ }$}$ }U}
$ }
}$ }}$ }$}$ }U}$
9
HARVARD BIOSCIENCE INC10K
03/11/2008Shareholders' Equity
Number Common
Additional
Accumulated
Accumulated Treasury
Total
of Shares
Stock
Paidin
Deficit
Other
Stock
Stockholders?IssuedCapital
ComprehensiveEquity
Income$
Balance at December 31, 2004
~
#
~
~
~
v
~
jX
~
t
~
~
^
Issuance of common stock
Stock option exercises~
?~
?
? ?~
Stock purchase plan~
?~
?
? ?~
Comprehensive income:
Net loss ? ? ?
~
? ?~
Translation adjustments ? ? ?
?
~
?~
%Minimum pension liability adjustment, ? ? ?
?
~
j ?~
j
net of tax
Total comprehensive loss ? ? ?
?
?~
$Balance at December 31, 2005~
%~
~~
~
Vf
~
1~
~
*"Initial application of SAB No. 108 ? ? ?
~
^
? ?~
^Stock option exercises~
~
~
?
? ?~
Stock purchase plan~
v ?~
?
? ?~
"Stock compensation expense ? ?~
?
? ?~
3+Impact of adopting SFAS No. 158, net of tax ? ? ?
?
~
?~
Comprehensive income:
Dlth<>0W3zl0 !"#$%&'()*+,./012345678 Net loss ? ? ?
~
n
? ~
n !Translation adjustments! !?!! !?!! !?! !
!?!!
!~
!>!!! !?!!!~
!>!"%Minimum pension liability adjustment," "?"" "?"" "?" "
"?""
"~
" """ "?"""~
" "#
net of tax$$$$$$$$$$ $
$$$
$$$$$$$$$$$"%Total comprehensive income% %?%% %?%% %?% %
%?%%
% %?%%% %?%%%~
%6#%&&&&&&&&&& &
&&&
&&&&&&&&&&&$'Balance at December 31, 2006'~
'^&'~
''~
'
' ~
'
I''
~
'z`''~
'''~
'.c'(Stock option exercises(~
(((~
(((~
( ( (
(?((
( (?((( (?(((~
( ()Stock purchase plan)~
)n)) )?))~
)) )
)?))
) )?))) )?)))~
))"*Stock compensation expense* *?** *?**~
*%* *
*?**
* *?*** *?***~
*%*+Comprehensive income:+++++++++ +
+++
+++++++++++,Net loss, ,?,, ,?,, ,?, ,
~
,,,
,,,,, ,?,,,~
,,0(Changes in defined benefit pension plans ? ? ? 
?
~
 ?~
.Translation adjustments. .?.. .?.. .?. .
.?..
.~
.... .?...~
..////////// /
///
/////////// 0Total comprehensive loss0 0?00 0?00 0?0 0
0?00
0 0?000 0?000~
0r01111111111 1
111
11111111111$2Balance at December 31, 20072~
2*2~
22~
2F
2 ~
2
322
~
2h22~
222~
2f23333333333 3
333
3333333333345$6____________________________17)Created by Morningstar Document Research.08(http://documentresearch.morningstar.com/62xbTo.Ik_S+=PF0*8X>
@Z+887766222222
222222''''''
''''''
l N^&=D
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }7}$ }
}$ }
}
$ }
}$
N
HARVARD BIOSCIENCE INC10K
03/11/2008
Cash Flows
Years ended December 31,
~
^
~
Z
~
V
%Cash flows from operating activities:
Net loss~
~
n ~
.
&Adjustments to reconcile net income to
2*net cash provided by operating activities:"Stock compensation expense~
%~
?Depreciation~
~
~
3+Loss on disposal of discontinued operations~
B0 ?
?,$Abandonment and impairment of assets~
,~
^<
~
&Noncash restructuring charges ? ?
~
9%Amortization of catalog costs~
~
~
~
2*(Gain) loss on disposal of property, plant~
~
~
and equipment)!Amortization of intangible assets~
~
~
)0(Amortization of deferred financing costs~
Z~
~
Deferred income taxes~
~
~
v4,Changes in operating assets and liabilities,
'net of effects of acquisitions:2*(Increase) decrease in accounts receivable~
~
:
~
&*"(Increase) decrease in inventories~
*~
~
/'Decrease in other receivables and other~
~
~
assetsDl~rOhZu1i>r
!
"
#
$
%
&
'
(
)
*
+
,

.
/
0
1
2
3
4
5
6
7
8
9
:
;
<
=
>
?
 %Increase (decrease) in trade accounts ~
~
6
~
!payable"%Increase (decrease) in accrued income""~
"n
"""~
""" "
~
""#
taxes payable/$'Increase (decrease) in accrued expenses$$~
$$$$~
$*$$ $
~
$$/%'Increase (decrease) in deferred revenue%%~
%%%%~
%J%% %
~
%j%%&Decrease in other liabilities&&~
&&&&~
&r&& &
~
&&'''''''''' '
''1()Net cash provided by operating activities((~
(^(((~
((( (
~
(.Q()))))))))) )
))*%Cash flows from investing activities:********* *
**2+*Additions to property, plant and equipment++~
+R+++~
+++ +
~
++",Additions to catalog costs,,~
,,,,~
,,, ,
,?,.&Proceeds from sales of property, plant ?~
 
~
b.
and equipment./&Net proceeds from sale of discontinued//~
//// /?// /
/?/0
operations*1"Acquisitions, net of cash acquired11~
1111~
111 1
1?12222222222 2
223%Net cash used in investing activities33~
3333~
333 3
~
3234444444444 4
445%Cash flows from financing activities:555555555 5
55%6Repayments of shortterm debt66~
6j666 6?66 6
6?6*7"Net proceeds from issuance of debt77~
7777 7?77 7
7?78Repayments of debt88~
8f888~
888 8
~
8829*Net proceeds from issuance of common stock99~
9J999~
999 9
~
99:::::::::: :
::;%Net cash used in financing activities;;~
;Z/;;;~
;j;; ;
~
;>;<<<<<<<<<< <
<</='Effect of exchange rate changes on cash==~
====~
=
== =
~
=j=>>>>>>>>>> >
>>?%Increase in cash and cash equivalents??~
????~
??? ?
~
??D?l9&_F}Y1e+,k8l m@
A
B
C
D
E
F
G
H
I
J
K
L
M
2@*Cash and cash equivalents at the beginning@@~
@^@@@~
@@@ @
~
@@A of periodBBBBBBBBBB B
BB6C.Cash and cash equivalents at the end of periodC~
CrCC~
C^CC ~
C
CDDDDDDDDDD D
DDE%Supplemental disclosures of cash flowEEEEEEEEE E
EEFinformation:GCash paid for interestG~
GGG~
GGG ~
G
G"HCash paid for income taxesH~
Hr#HH~
HHH ~
H
&HIJ$K____________________________1L)Created by Morningstar Document Research.0M(http://documentresearch.morningstar.com/ 4;zb6*=PF0*8X>
@MMLLKKHHHHHH
GGGGGG
CCCCCC
l V
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0.}$ }}$ }U} $ }
HARVARD BIOSCIENCE INC10K
03/11/2008?7Consolidated Statements of Stockholders#146; Equity and
Before Adjustments
After
Application of
Increase
Application ofSFAS No. 158
(Decrease) SFAS No. 158(in thousands).
&Deferred income tax assets?noncurrent
~
*
~
~
Total assets~
~
~
%Other liabilities?noncurrent~
~
# ~
>$Total liabilities~
)~
# ~
M.&Accumulated other comprehensive income~
ry~
~
z`"Total stockholders? equity~
&~
~
.c$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4. i]QEKEJ[OC=PF0*8X>
@
l c
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }%}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008?7Consolidated Statements of Stockholders#146; Equity and Buildings 40 years
Machinery and equipment
310 years'Computer equipment and software 37 yearsFurniture and fixtures
510 years
Automobiles
36 years$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*Fhi]QE![=PF0*8X>
@
l \r
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }
}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008?7Consolidated Statements of Stockholders#146; Equity and December 31,
~
^
~
Z(in thousands)Finished goods~
J~
&:
Work in process
~
~
Raw materials~
~
U~
~
ާ$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2(i]QEO5MA5
=PF0*8X>
@Z
l #
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }2}$ }
}$ }
}$
HARVARD BIOSCIENCE INC10K
03/11/2008?7Consolidated Statements of Stockholders#146; Equity and December 31,
~
^
~
Z
(in thousands)2*Land, buildings and leasehold improvements~
V(~
~'
Machinery and equipment
~
n[
~
~Q
'Computer equipment and software~
N6~
Furniture and fixtures~
Z
~
Automobiles~
~
~
~
&Less: accumulated depreciation~
y~
*"Property, plant and equipment, net~
E~
H$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<
i]QEEon6=PF0*8X>
@j
l $m
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3)Anthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }:}$ }}$
$
HARVARD BIOSCIENCE INC10K
03/11/2008Panlab s.l. (in thousands)
Tangible assets
~
;
Liabilities assumed~
,$Notes payable and other debt assumed~
R
Net liabilities assumed~
'Goodwill and intangible assets:Goodwill~
zD1)Other indefinite lived intangibles (trade~
name)80Distribution agreements / customer relationships~
Existing technology~
Noncompete agreements~
Deferred tax liabilities~
%Total goodwill and intangible assets,~
NY
net of tax7/Cash paid for acquisition, net of cash acquired~
"TD~ l}q5er6.F`J !"# $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/<=PF0*8X>
@2##""!!
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab sl
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }1}$ }U
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos (in thousands)
Tangible assets
~
Intangible assets:
Existing technology
~
R1)Other indefinite lived intangibles (trade~
b
name)Total intangible assets~
!Cash paid for acquisition~
z$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8
vFm(Cd=PF0*8X>
@2
l ڻ
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }}$ }}
$ }
}$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos
Years Ended December 31,
~
^
~
Z
~
V
(in thousands)Total revenues~
V~
~
VY
Pretax loss~
F~
x
~
V$Income tax (benefit) expense~
~
~
.&Loss from discontinued operations, net~
b~
s
~
jof tax7/Loss on disposition of discontinued operations,~
?
?
net of tax
0(Total loss from discontinued operations,~
"t~
s ~
j
net of tax
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/@
DvJCL=PF0*8X>
@r
l u
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }
}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z(in thousands)Assets!
Cash and cash equivalents
~
~
* Accounts receivable, net~
~
SInventories~
V~
Other assets~
~
Longlived assets~
~
Total assets~
B~
LiabilitiesTotal liabilities~
~
*O$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>0v"&]95)=PF0*8X>
@j
l $b
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }6}$ }U}$ } } $ }
U}$ }
}$ }
$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos
December 31, Weighted
~
^
~
Z
Average
GrossAccumulated
GrossAccumulatedLife(a)Amortization
Amortization
(in thousands)
&Amortizable intangible assets:Existing technology~
~
~
~
6.7 years Tradename~
b~
B ~
b~
: 7.1 years5Distribution agreement/customer relationships~
Nb~
~
FJ~
7.8 yearsPatents~
&~
~
&~
8.3 years
+#Total amortizable intangible assets~
f2~
s~
~
( Unamortizable intangible assets:
Goodwill~
~
e
0(Other indefinite lived intangible assets~
~
1)Total goodwill and other indefinite lived~
~
jv
intangible assets
Total intangible assets~
~
6
DlvNlD}
A`Cw !"# $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/<=PF0*8X>
@##""!!
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos (in thousands)$
Balance at December 31, 2005
~
R9&Impact of adopting SAB No. 108~
~.&Effect of change in foreign currencies~
$Balance at December 31, 2006~
e0(Goodwill acquired during the year (based~
C"on preliminary allocation).&Effect of change in foreign currencies~
r$Balance at December 31, 2007~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8svF*^8n>2&=PF0*8X>
@:
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }
}$ }$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z(in thousands)Longterm debt~
U~
.
Notes payable (Panlab)
~
#
?~
y~
."Less: current installments~
?Longterm debt~
*W~
.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6Kvh5lRF:=PF0*8X>
@j
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U } }$ }
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos (in thousands)~
b
~
!~
f~
U~
j~
Total~
y$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.TvFT)=PF0*8X>
@2
l &
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }U
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos Operating
Leases(in thousands)~
b~
~
f
~
:~
j~
V~
n~
R~
r~
Thereafter~
b"Net minimum lease payments~
8$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8vFaY=PF0*8X>
@B
l l5
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }*}$ }U}$ }U
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z(in thousands)( Accrued compensation and payroll~
~~
#+
#Accrued legal and professional fees
~
B
~
JWarranty costs~
~
Other~
~
V
Total~
@~
RB$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4v" ?I=PF0*8X>
@Z
l +L
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0.}$ }
}$ }
}
$ }
}$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos
Years ended December 31,
~
^
~
Z
~
V
(in thousands)%Current income tax expense (benefit):
Federal and state
~
~
~
r
Foreign~
$~
~
~
:$~
~
:
.&Deferred income tax (benefit) expense:
Federal and state~
~
~
Foreign~
~
~
~
~
~
Total income tax expense~
~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/B
XvA'ewE9=PF0*8X>
@
l %fig
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }6}$ }U}$ } }
$ }U}$
%
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos
Years ended December 31,
~
^
~
Z
~
V
(in thousands).&Computed ?expected? income tax expense~
2~
, ~
%5
Increase (decrease) in income taxes resulting
from:"Permanent differences, net~
~
J
~
4,Foreign tax rate and regulation differential~
f~
~
1)State income taxes, net of federal income~
~
~
btax benefit!Foreign withholding taxes~
~
*
~
)!Impact of discontinued operations~
~
~
v)!Utilization of net operating loss ?~
?1)Nondeductible stock compensation expense~
~
?%Federal tax expense differential from~
*~
n
?prior year taxTax credits~
>~
~
~
/'Change in valuation allowance allocated~
M~
2*
~
to income tax expense
Other~
~~
^
~
Total income tax expense~
~
~
Dlv2iX1nVl)
!
"
#
$
!$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/
P=PF0*8X>
@r$$##""
l v
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }y
}$ }
}$ }
}$ }
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos Years ended December 31,
~
^
~
Z
~
V(in thousands)Domestic~
~
z~
1
Foreign
~
}
~
k
~
= ~
~
2~
o $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0\vh6O}=PF0*8X>
@r
l )8
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }a/}$ }U}$ }U}$
)
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos Years ended
December 31,~
^~
Z(in thousands)
Deferred tax assets:
Accounts receivable~
6~
j Inventory~
~
f/'Operating loss and credit carryforwards~
~
ZB%Property, plant and equipment~
?Accrued expenses~
~
^
Pension liabilities~
j~
!Other accrued liabilities~
~
#Total gross deferred assets~
~
h!Less: valuation allowance~
V ~
rDeferred tax assets~
!~
)!Deferred tax liabilities:%Property, plant and equipment
$?~
nIntangible assets~
0~
:)!Other accrued liabilities~
r~
D
lv
G v
39 ! " # $ % & ' ( & Total deferred tax liabilities ~
7 ~
n4 !!!!!!!!!""Net deferred tax liability"~
"""~
""#########$%$&____________________________1')Created by Morningstar Document Research.0((http://documentresearch.morningstar.com/5r(=PF0*8X>
@((''&&""""
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }U}$ }U}
$ }U}$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos
Years ended December 31,
~
^
~
Z
~
V
(in thousands)0(Components of net periodic benefit cost:
Service cost
~
*
~
~
Interest cost~
*~
~
^&Expected return on plan assets~
~
~
~
*Net amortization loss~
~
~
!Net periodic benefit cost~
~
J ~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6
vb/{S=PF0*8X>
@r
l 0ٺ
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }+}$ }U}$ }U}$
0
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z
(in thousands)%Change in benefit obligation:$
Balance at beginning of year
~
~
Service cost~
*~
Interest cost~
*~
#Participants? contributions~
N~
&Actuarial (gain) loss~
~
Benefits paid~
~
Z'Currency translation adjustment~
j~
: Balance at end of year~
~
,$Change in fair value of plan assets:$Balance at beginning of year~
R~
$Actual return on plan assets~
~
^#Participants? contributions~
N~
&Employer contributions~
6~
&
Benefits paid~
~
Z
Expenses paid~
~
~'Currency translation adjustment~
~
D6lv
v8;B2&LPP?E ! " # $ % & ' ( ) * + ,  . / Balance at end of year ~
: ~
R !!!!!!!!!""###December 31,#$$~
$^$$~
$Z$%%%(in thousands)%&
Funded status&~
&&&~
&V&'Unrecognized net loss'''N/A''''N/A'((((((((()Net amount recognized)~
)))~
)V)*********+,$____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,&z
@//..))))&&&&%%$$$$##
l ~
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }}$ }}$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z
(in thousands)"Deferred income tax assets~
j~
Other liabilities
~
~
V
Net amount recognized~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0av
v8El=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }*}$
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos December 31,
~
^
~
Z
(in thousands)+#Underfunded status of pension plans~
~
Net amount recognized~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.v
v8Qxl`8=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }y#}$ } }$}$ } }$}$ } } $
HARVARD BIOSCIENCE INC10K
03/11/2008Anthos Years ended December 31,
~
^
~
Z
~
V
Discount rate=
ףp=@ %Q@ %@ %!Expected return on assets@ %Q@ %@ %%
Rate of compensation increase
=
ףp=@
%
Gz@
%
@
%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hv8NB6=PF0*8X>
@"
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }m)}$ }}$}$ }}$}$ }} $
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Years Ended December 31,
~
^
~
Z
~
V
*"Shares of common stock outstanding~
[~
aI~
uD
Granted
~
eE
~
SH
~
)
Canceled / forfeited~
~
~
Net options granted~
1~
v>~
2t Grant dilution(1)@ %p=
ף
@ %ffffff? % Exercised~
~
/~
. Exercise dilution(2)333333? %(\? %{Gz? %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:
ui]QsC,#
Vu=PF0*8X>
@"
l &
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }}$ }}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Years Ended December 31,
~
^
~
Z
~
V
Basic~
N~
θF~
B0(Effect of assumed conversion of employee~
W.~
l&~
"
and director stock optionsDiluted~
~
%m~
*V$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0
ui]Qg`WK?=PF0*8X>
@"
l $'(
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }y#}$ }}$ }}$ }
$
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Options Options Weighted
Available
Outstanding
Average for GrantExercise Price$Balance at December 31, 2004~
B>*~
p=
ף@
Options granted
~
RH
~
)
{Gz@Options exercised ?~
@%Options cancelled / forfeited~
C~
(\@"Additional shares reserved~
Z ? $Balance at December 31, 2005~
j~
O)\(@ Approved by shareholders~
z ? ?Options granted~
b~
SH q=
ףp@Options exercised ?~
(\@%Options cancelled / forfeited~
.<
~
=
ףp=@ $Balance at December 31, 2006~
Q~
6@\(\@Options granted~
b~
eE p=
ף@Options exercised ?~
p=
ף@%Options cancelled / forfeited~
[~
ףp=
@ $Balance at December 31, 2007~
> ~
;a(\@ Dlui]QWM*dZ5i8.
!
"
#
$!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/<=PF0*8X>
@R
## "" !!
l A
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }0}$ }} $ }
U}$ }0}
$ }U
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options
Options Outstanding Options Exercisable
Range of
Number
Weighted
Weighted
Aggregate
Shares
Weighted
AggregateExerciseOutstanding atAverageAverage IntrinsicExercisable at
Average Intrinsic
PriceDecember 31, 2007 RemainingExercise
ValueDecember 31, 2007
Exercise
Value
Contractual Life
Price
Pricein Years
$0.013.16~
cIRQ@p=
ף@~
~
G:
=
ףp=@~
$3.174.23~
#333333@\(\
@ ~
2~
k
Q
@~
$4.244.56~
¿C\( @{Gz@ ~
~
bx
{Gz@~
$4.577.20~
2dGz@Gz@
?~
$
333333@ ?$7.2110.00~
L{Gz@L @
?~
bp>
L @ ?
$0.0110.00~
;a=
ףp=@(\@~
,~
p=
ף@~
n"
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<ui]QmZ>N^p=PF0*8X>
@#
l VR
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }$}$ }U}$ }U
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Years Ended
December 31,~
^~
Z
Cost of sales~
~
Sales and marketing
~
~
"General and administrative~
!~
v Research and development~
~
2Discontinued operations~
~
&Total stockbased compensation~
%~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6Nui]Q^4UOC7=PF0*8X>
@Z
l %khl
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }}$ }}
$ }}$
%
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options
Years Ended December 31,
~
^
~
Z
~
V
%(in thousands, except per share data)/'Net income (loss), as reported in priorN/AN/A ~
periods(1).&Add: stockbased employee compensation ? ?
?/'expense included in reported net income(loss), net of tax7/Deduct: total stockbased employee compensation~
n~
~
1)expense determined under fairvalue based,$method for all awards, net of tax(2)
6.Net loss including stockbased compensation(3)~
~
n ~
Income (loss) per share:
Basic?as reported(1)N/AN/A
3+Basic?including stockbased compensation(3){Gz{Gz
ffffff
Diluted?as reported(1)N/AN/A
p=
ף
5Diluted?including stockbased compensation(3){Gz{Gz
(\
Dlui]Qmy11D
!
"
#
$
!$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/
P=PF0*8X>
@$$##""
l {
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }U}$ }}$ }}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Years Ended December 31,
~
^
~
Z
~
V
Volatility70.46%75.99%94.72%Riskfree interest rate
4.60%
4.82%
3.85%
Expected holding period
6.25 years
6.25 years
4 yearsDividend yield
0.00%
0.00%
0.00%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,ui]Qg}znF=PF0*8X>
@"
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }}$ }}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Years ended December 31,
~
^
~
Z
~
V(in thousands)
United States~
'~
.~
f
United Kingdom
~
~
~
Rest of the world~
~
6~
~
>~
V~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/20ui]QCE9=PF0*8X>
@r
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }
}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options December 31,
~
^
~
Z(in thousands)
United States~
!~
*$
United Kingdom
~
~
Rest of the world~
~
~
E~
H$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2ui]Q[?WK?=PF0*8X>
@Z
l e
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }0}$ }}$ }
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options December 31,
~
^
~
Z(in thousands)
United States~
~
z
United Kingdom
~
r
~
xRest of the world~
:~
Ƅ~
b_~
֣$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2ui]Q[?WK?=PF0*8X>
@Z
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }I"}$ }0}$ }} $ }
}$
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options
Beginning Beginning Balance
Charged to
Writeoffs
Ending
Balance
Reclassified to
Bad Debt
Charged to
BalanceDiscontinuedExpense
Allowance
Operations
(in thousands)$Year ended December 31, 2005~
V
~
~
& ~
"~
n$Year ended December 31, 2006~
n ?~
n ~
~
$Year ended December 31, 2007~
?~
b ~
~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ui]Qb[Z=PF0*8X>
@r
l [
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }I"}$ }0}$ }y
}
$ }<}$
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options
Beginning Beginning Balance Payments
Additions(a)
Ending
Balance
Reclassified to
BalanceDiscontinued
Operations
(in thousands)$Year ended December 31, 2005~
~
~~
~
B~
$Year ended December 31, 2006~
?~
~
v~
$Year ended December 31, 2007~
?~
z
~
z~
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0iui]Qn
@r
l ^
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }2}$ }
}$ }U} $ }
$
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options
Years ended December 31,
~
^
~
Z
~
V(in thousands)/'Cash paid for acquisitions, net of cash
acquired:2*Net assets acquired or liabilities assumed~
:~
$?.&Goodwill and intangible assets, net of~
NY~
?tax"Less cash acquired, if any~
?
?
/'Cash paid for acquisitions, net of cash~
"T~
z
$?acquired
$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:% ui]Q+N9I8$`=PF0*8X>
@r
l
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }1}$ }
}$ }
}$
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options As of December 31,
~
^
~
Z
(in thousands).&Balances included in accumulated other
comprehensive income:)!Cumulative translation adjustment~
"\~
`,$Cumulative translation adjustment on~
~
1)investment type loans, net of tax of $710and $678, respectively1)Defined benefit pension plans, net of tax~
~
benefit of $346 and $685Balance~
h~
z`$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<ui]QK
}H&i2&=PF0*8X>
@Z
l B//
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }
}$ }}
$ }}$ }}$ }}$
B
HARVARD BIOSCIENCE INC10K
03/11/2008Income Statement
~
^
First Second
Third
Fourth Fiscal
Quarter
Quarter
Quarter
Quarter
Year%(in thousands, except per share data)Revenues~
*~
> ~
f.
~
F~
>
Cost of product revenues
~
z
~
~
v
~
~
f
Gross profit~
6~
~
~
~
t$Sales and marketing expenses~
&~
'
~
j&
~
,~
¡+#General and administrative expenses~
.5~
b7
~
6
~
vD~
)!Research and development expenses~
2
~
~
~
>~
96.Amortization of goodwill and other intangibles~
~
~
~
~
Total operating expenses~
o~
t
~
q
~
F~
Operating income~
Z#~
'
~
B
~
r*~
#Other income (expense), net~
6~
~
R
~
&~
0(Income from continuing operations before~
#~
'
~
~
)~
income taxesIncome taxes~
V~
V
~
~
J~
)!Income from continuing operations~
:~
~
~
~
N$~
v
D{lxlpiy}kI xN6$( !"#$%&'()*+,./0123456789:;<=>? Discontinued operations
.!&Loss from discontinued operations, net!!~
!!!!~
!!! !
~
!V!!
!~
!!!!~
!b!"of tax7#/Loss on disposition of discontinued operations,## #?### #?## #
#?##
#~
####~
##$
net of tax%%%%%%%%%% %
%%%
%%%%%%%0&(Total loss from discontinued operations,&&~
&&&&~
&&& &
~
&V&&
&~
&Z&&&~
&"t&'
net of tax(((((((((( (
(((
((((((()Net income (loss))~
)))~
)j)) ~
)
))
~
)))~
))********** *
***
******* +Income (loss) per share:+++++++++ +
+++
+++++++7,/Basic earnings per common share from continuing,,Q?,,,Q?,, ,
?,,
,{Gz?,,,?,
operations.Discontinued operations...{Gz....Q.. .
.{Gz..
..Q....(\ҿ.////////// /
///
///////'0Basic earnings per common share00{Gz?000Q00 0
{Gz?00
0{Gz000{Gz01111111111 1
111
1111111.2&Diluted earnings per common share from22Q?222Q?22 2
?22
2Q?222Q?23continuing operations4Discontinued operations444{Gz4444Q44 4
4{Gz44
44Q4444(\ҿ45555555555 5
555
5555555)6!Diluted earnings per common share66{Gz?666Q66 6
{Gz?66
6{Gz666{Gz67777777777 7
777
7777777'8Weighted average common shares:888888888 8
888
8888888
9Basic99~
9999~
999 9
~
999
9~
9F999~
99:::::::::: :
:::
:::::::;Diluted;;~
;;;;~
;6;; ;
~
;;;
;~
;Z;;;~
;;<<<<<<<<<< <
<<<
<<<<<<<=>$?____________________________DAl}gk='+PT@3{s@A1@)Created by Morningstar Document Research.0A(http://documentresearch.morningstar.com/=PF0*8X>
@b,AA@@??666666
6666222222
2222000000
0000,,,,,,
,,,,))))))
))))
l BsTpq
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)!Distribution and Dilutive (14)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }8}$ }
}$ }
}
$ }
}$ }}$ }}$
B
HARVARD BIOSCIENCE INC10K
03/11/2008Income Statement
~
Z
First Second
Third
Fourth Fiscal
Quarter
Quarter
Quarter
Quarter
Year%(in thousands, except per share data)Revenues~
j~
. ~
'
~
R~
V
Cost of product revenues
~
~
Ƌ
~
~
&
~
:S
Gross profit~
~
j
~
N
~
~
S$Sales and marketing expenses~
#~
$
~
."
~
)~
n+#General and administrative expenses~
1~
65
~
?
~
VD~
)!Research and development expenses~
~
~
~
~
J16.Amortization of goodwill and other intangibles~
r~
~
~
~
Total operating expenses~
g~
l
~
6u
~
Ɓ~
V
Operating income~
#~
#
~
~
#~
ʇ#Other income (expense), net~
6~
f
~
n
~
f~
j
0(Income from continuing operations before~
:!~
.#
~
~
J#~
2income taxesIncome taxes~
~
J
~
~
~
)!Income from continuing operations~
"~
~
~
~
vg
D{lxlpiy}kI xN6$( !"#$%&'()*+,./0123456789:;<=>? Discontinued operations
.!&Loss from discontinued operations, net!!~
!R!!!~
!!! !
~
!N!!
!~
!R!!!~
!s!"of tax7#/Loss on disposition of discontinued operations,## #?### #?## #
#?##
# #?### #?#$
net of tax%%%%%%%%%% %
%%%
%%%%%%%0&(Total loss from discontinued operations,&&~
&R&&&~
&&& &
~
&N&&
&~
&R&&&~
&s&'
net of tax(((((((((( (
(((
((((((()Net income (loss))~
)r))~
))) ~
)
6))
~
)))~
)n)********** *
***
******* +Income (loss) per share:+++++++++ +
+++
+++++++7,/Basic earnings per common share from continuing,,?,,,Q?,, ,
{Gz?,,
,Q?,,,)\(?,
operations.Discontinued operations...Q....Q뱿.. .
...
..Q....(\ҿ.////////// /
///
///////'0Basic earnings per common share00{Gz?000{Gz00 0
{Gz00
0{Gz000{Gz01111111111 1
111
1111111.2&Diluted earnings per common share from22?222Q?22 2
{Gz?22
2Q?222zG?23continuing operations4Discontinued operations444Q4444Q뱿44 4
444
44Q4444(\ҿ45555555555 5
555
5555555)6!Diluted earnings per common share66{Gz?666{Gz66 6
{Gz66
6{Gz666{Gz67777777777 7
777
7777777'8Weighted average common shares:888888888 8
888
8888888
9Basic99~
9r999~
999 9
~
9
99
9~
9R999~
99:::::::::: :
:::
:::::::;Diluted;;~
;;;;~
;;; ;
~
;n;;
;~
;;;;~
;;<<<<<<<<<< <
<<<
<<<<<<<=>$?____________________________D?lim?)RVB5}u@A1@)Created by Morningstar Document Research.0A(http://documentresearch.morningstar.com/=PF0*8X>
@b,AA@@??666666
6666222222
2222000000
0000,,,,,,
,,,,))))))
))))
l &j
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (15)!Distribution and Dilutive (16)U }}$ }8}$ }
&
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options Signature
Title Date
/ S / C HANE G RAZIANO7/Chief Executive Officer and Director (PrincipalMarch 11, 2008Chane GrazianoExecutive Officer)
/ S / B RYCE C HICOYNE4,Chief Financial Officer (Principal FinancialMarch 11, 2008Bryce Chicoyne1)Officer and Principal Accounting Officer) / S / D AVID G REENPresident and DirectorMarch 11, 2008David Green / S / R OBERT D ISHMANDirectorMarch 11, 2008Robert Dishman / S / N EAL J. H ARTEDirectorMarch 11, 2008
Neal J. Harte / S / J OHN F. K ENNEDYDirectorMarch 11, 2008John F. Kennedy / S / E ARL R. L EWISDirectorMarch 11, 2008
Earl R. LewisD. lui]Q(iE6 !"#$% / S / G EORGE U VEGES Director March 11, 2008!
George Uveges"$#____________________________1$)Created by Morningstar Document Research.0%(http://documentresearch.morningstar.com/d~rJ=PF0*8X>
@%%$$##
l jա+
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (16)U }
}$ }=
j
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options ~
4
,Asset Purchase Agreement, dated November 30,.&2007, by and among Harvard Bioscience,0(Inc., as Parent, Genomic Solutions Inc.,
2
*Genomic Solutions, Ltd., Genomic Solutions/'Acquisitions Limited, Union Biometrica,/'Inc., and Cartesian Technologies, Inc.,.&collectively, as Sellers, and Digilab,Inc., as Buyer~
/'Second Amended and Restated Certificate3+of Incorporation of Harvard Bioscience, Inc~
/'Amended and Restated Bylaws of HarvardBioscience, Inc~
/'Amendment No. 1 to Amended and Restated.&Bylaws of Harvard Bioscience, Inc. (as!adopted October 30, 2007)~
0(Certificate of Designations, Preferences1)and Rights of a Series of Preferred Stock/'of Harvard Bioscience, Inc. classifyingDlui]QyIhi}/ !"#$%&'()*+,./0123456789:;<=>? 9 1and designating the Series A Junior Participating!!"!Cumulative Preferred Stock""~
##1#)Specimen certificate for shares of Common$$;$3Stock, $0.01 par value, of Harvard Bioscience, Inc.%%~
&&&%Amended and Restated Securityholders?''2'*Agreement dated as of March 2, 1999 by and((.(&among Harvard Apparatus, Inc., Pioneer)).)&Partnership II, Pioneer Capital Corp.,**4*,First New England Capital, L.P. and Citizens++2+*Capital, Inc. and Chane Graziano and David,,,Green.~
..,.$Shareholders Rights Agreement, dated//:/2as of February 5, 2008 between Harvard Bioscience,0010)Inc., and Registrar and Transfer Company,111as Rights Agent.22~
3313)Harvard Apparatus, Inc. 1996 Stock Option444and Grant Plan.55~
6656Harvard Bioscience, Inc. Amended and Restated777%2000 Stock Option and Incentive Plan.88~
99/9'Harvard Bioscience, Inc. Employee Stock:::Purchase Plan.;;~
<<,<$Employment Agreement between Harvard==,=$Bioscience, Inc. and Chane Graziano.>>~
??,?$Employment Agreement between HarvardD
lmULj@iQdl"@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_@@)@!Bioscience, Inc. and David Green.AA~
BB3B+Form of Director Indemnification Agreement.CC~
DD2D*Lease of Unit 22 Phase I Cambridge ScienceEE3E+Park, Milton Road, Cambridge dated March 3,FF4F,1999 between The Master Fellows and ScholarsGG.G&of Trinity College Cambridge, BiochromHH+H#Limited and Harvard Apparatus, Inc.II~
JJ0J(Lease between Genomic Solutions Inc. andKK/K'Highland Industrial Properties, L.L.C.,LLLdated August 7, 1997MM~
NN0N(Fourth Addendum to Lease between GenomicOO.O&Solutions Inc. and Highland IndustrialPP.P&Properties, L.L.C., dated May 17, 2000QQ~
RR/R'Fifth Addendum to Lease between GenomicSS.S&Solutions Inc. and Highland IndustrialTT/T'Properties, L.L.C., dated September 10,UU~
UFVV~
WW2W*Lease between Cartesian Technologies, Inc.XXX%and Airport Industrial Complex, datedYYYFebruary 5, 2002ZZ~
[[0[(Lease between Genomic Solutions Inc. and\\.\&County Road Properties, dated March 8,]].]&2003 and First Addendum thereto, dated^^^March 10, 2003__D lR:KT k!r(Ol"`abcdefghi~
``.`&Revolving Credit Loan Agreement, datedaa5aas of November 21, 2003, by and among Harvardbb.b&Bioscience, Inc., the Lenders that arecc.c&signatories thereto and Brown BrothersdddHarriman & Co.ef$g____________________________1h)Created by Morningstar Document Research.0i(http://documentresearch.morningstar.com/c]=PF0*8X>
@iihhgg
l UvC
dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??>
NO TITLENO TITLE (1)NO TITLE (2)Gel Electrophoresis Systems!The divestiture of the remaininSusan LuscinskiSusan Luscinski (1)Income StatementSusan Luscinski (2)!The following section of this A!Overview of Cash Flows for the Overview of Cash Flows for (1)Impact of Foreign CurrenciesSummary CompensationBeneficial OwnershipImpact of Foreign Curren (1)!I NDEX TO CONSOLIDATED FINANCIA
Balance SheetIncome Statement (1)Shareholders Equity
Cash Flows!Consolidated Statements of Stoc!Consolidated Statements of (1)!Consolidated Statements of (2)!Consolidated Statements of (3) Panlab slAnthos
Anthos (1)
Anthos (2)
Anthos (3)
Anthos (4)
Anthos (5)
Anthos (6)
Anthos (7)
Anthos (8)
Anthos (9)
Anthos (10)
Anthos (11)
Anthos (12)
Anthos (13)
Anthos (14)
Anthos (15)
Anthos (16)
Anthos (17)!Distribution and Dilutive Effec!Distribution and Dilutive E (1)!Distribution and Dilutive E (2)!Distribution and Dilutive E (3)!Distribution and Dilutive E (4)!Distribution and Dilutive E (5)!Distribution and Dilutive E (6)!Distribution and Dilutive E (7)!Distribution and Dilutive E (8)!Distribution and Dilutive E (9)!Distribution and Dilutive (10)!Distribution and Dilutive (11)!Distribution and Dilutive (12)!Distribution and Dilutive (13)Income Statement (2)Income Statement (3)!Distribution and Dilutive (14)!Distribution and Dilutive (15)U }y}$ }7
U
HARVARD BIOSCIENCE INC10K
03/11/20083+Distribution and Dilutive Effect of Options ~
2
*Letter Agreement among Harvard Bioscience,3+Inc., Brown Brother Harriman & Co. and Bank3+of America, N.A. dated as of March 14, 2006
.
&amending that certain Revolving Credit/'Loan Agreement dated as of November 21,2003 among the parties~
0(Second Amendment to the Revolving Credit4,Loan Agreement dated as of December 1, 2006,.&by and among Harvard Bioscience, Inc.,0(the Lenders that are signatories thereto)!and Brown Brothers Harriman & Co.~
6.Lease, dated February 23, 2004, by and between,$William Cash Forman and Hoefer, Inc. +(9)10.186.Trademark License Agreement, dated December 9,52002, by and between Harvard Bioscience, Inc.5and President and Fellows of Harvard College.~
/'Harvard Bioscience, Inc. 2007 Corporate
Bonus PlanD lui]Qv'X@X[O !"#$%&'()*+,./0123456789:;<=>? ~
!!/!'Form of Employment Agreement with Susan""4",M. Luscinski and Bryce Chicoyne (and summary##0#(of significant terms for each Employment$$$
Agreement)%%~
&&3&+Lease Agreement Between Seven October Hill,''.'&LLC and Harvard Bioscience, Inc. dated(((December 30, 2005))~
****"Director Compensation Arrangements++~
,,0,(Form of Incentive Stock Option AgreementExecutive Officers..~
//4/,Form of NonQualified Stock Option Agreement000Executive Officers11~
2242,Form of NonQualified Stock Option Agreement33'3NonEmployee Board of Directors4455@5'5Subsidiaries of the Registrant.6677@77Consent of KPMG LLP.889?@909(Certification of Chief Financial Officer:::%of Harvard Bioscience, Inc., pursuant;;4;,to Rules 13a15(e) and 15d15(e), as adopted<<5<pursuant to Section 302 of the SarbanesOxley===Act of 2002.>>?333333?@?0?(Certification of Chief Executive OfficerD lKhq#M5?'6e@ABCDEFGHIJKLMNOPQRST@@@%of Harvard Bioscience, Inc., pursuantAA4A,to Rules 13a15(e) and 15d15(e), as adoptedBB5Bpursuant to Section 302 of the SarbanesOxleyCCCAct of 2002.DD
E32.1*E0E(Certification of Chief Financial OfficerFFF%of Harvard Bioscience, Inc., pursuantGG6G.to 18 U.S.C. Section 1350, as adopted pursuantHH0H(to Section 906 of the SarbanesOxley ActIIIof 2002.JJ
K32.2*K0K(Certification of Chief Executive OfficerLLL%of Harvard Bioscience, Inc., pursuantMM6M.to 18 U.S.C. Section 1350, as adopted pursuantNN0N(to Section 906 of the SarbanesOxley ActOOOof 2002.PQ$R____________________________1S)Created by Morningstar Document Research.0T(http://documentresearch.morningstar.com/._g}4jRf=PF0*8X>
@TTSSRR
Root Entry FBook
u
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~
!"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{}~